Status:
RECRUITING
Combined Anabolic Therapy
Lead Sponsor:
Massachusetts General Hospital
Collaborating Sponsors:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Conditions:
Osteoporosis, Postmenopausal
Osteoporosis
Eligibility:
FEMALE
45+ years
Phase:
PHASE4
Brief Summary
In this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmenopausal osteoporosis.
Eligibility Criteria
Inclusion
- women aged 45+
- postmenopausal
- osteoporotic with high risk of fracture
Exclusion
- no significant previous use of bone health modifying treatments
- known congenital or acquired bone disease other than osteoporosis
- significant renal disease, liver disease, cardiopulmonary disease, or psychiatric disease
- abnormal calcium or parathyroid hormone level
- serum vitamin D \<20 ng/dL
- anemia (hematocrit \<32%)
- history of malignancy (except non-melanoma skin carcinoma)
- excessive alcohol use or substance abuse
- known contraindications to romosozumab or teriparatide
Key Trial Info
Start Date :
February 3 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2027
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06558188
Start Date
February 3 2025
End Date
July 1 2027
Last Update
March 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114